Skip to main content
. Author manuscript; available in PMC: 2020 Mar 29.
Published in final edited form as: Gynecol Oncol. 2019 Dec 13;156(2):423–429. doi: 10.1016/j.ygyno.2019.12.003

Fig. 2.

Fig. 2.

AKaplan-Meier curve forprogression-free survival (PFS) by EZH2 mRNAexpression level in tumor tissue (Hazard Ratio (HR) = 0.59,95% CI = 0.178–1.769; log-rank test p-value = .3611 ) (EZH2 mRNA: Low [≤median] vs High [>median]) B. Kaplan-Meier curve for PFS by EZH2 protein expression in tumor tissue (HR = 0.307,95% CI 0.047–1.143; log-ranktest p-value 0.117) (EZH2 protein: negative vs positive) C. Kaplan-Meier curve for overall survival (OS) by EZH2 mRNAexpression level in tumor tissue (HR = 1.292,95% CI 0.285–6.556; log-ranktest p-value 0.737) D. Kaplan-Meier curve for OS by EZH2 protein expression in tumor tissue (HR = 0.289,95% CI 0.015–1.692; log-rank test p-value 0.221 ).